Approval · Notice of Compliance 37260 · 2026
ADHEROZA: Notice of Compliance 37260
Issued March 24, 2026
A Notice of Compliance is Health Canada’s approval of a drug submission: a new drug, a new use or form, or a change to an approved one. The product itself is in the Drug Product Database, with its current status.
- Notice number
- 37260
- Date
- March 24, 2026
- Company
- Accord Healthcare IncKirkland, Quebec, Canada
- Product type
- Biologic
- Submission
- Supplement to a New Drug Submission (SNDS), supplement
- Submission class
- Other
- Reason
- Addition of a diluent for the drug product
- Canadian reference product
- HERCEPTIN
Products in this notice
| Brand | DIN | Status today |
|---|---|---|
| ADHEROZA | Not yet assigned | — |
Medicinal ingredients
- TRASTUZUMAB 150 MG per VIAL
- TRASTUZUMAB 420 MG per VIAL